Morgan & Morgan Announces Investigation of MAP Pharmaceuticals (NASDAQ: MAPP)
NEW YORK, Jan. 30, 2013
NEW YORK, Jan. 30, 2013 /PRNewswire/ --Morgan & Morgan is investigating the
Board of Directors of MAP Pharmaceuticals Inc. ("MAP" or the "Company")
(Nasdaq: MAPP) for possible breaches of fiduciary duty and other violations of
law related to the sale of the Company to Allergan Inc.
If you are a current shareholder of MAP and are interested in learning more
about our MAP Pharmaceuticals merger investigation, please contact George
Pressly, Esq. at1 (800) 631-6234or email George at
Under the terms of the transaction, MAP shareholders will receive $25 for each
share of MAP stock they own. The transaction has a total approximate value of
$958 million. The investigation concerns whether the MAP Board of Directors
has breached its fiduciary duties to act in the best interests of MAP
shareholders and to take all necessary steps to ensure that MAP shareholders
receive the maximum value readily available for their shares of MAP common
About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to
securities fraud, the firm also practices in the areas of antitrust, personal
injury, consumer protection, overtime, and product liability.All of the
Firm's legal endeavors are rooted in its core mission: provide investor and
consumer protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar outcome.
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44^th Street
New York, NY 10036
SOURCE Morgan & Morgan
Press spacebar to pause and continue. Press esc to stop.